Acquisition and merger agreements always make a huge buzz in news headlines of finance and business.
Selecting Decoy Biosystems as a part of the main business was a genuine decision of Intec to survive and move on in hard competition having biotech industry. Developing therapeutics and drugs for patients with tumors and cancer has been a complicated and a lot of resources consuming task for any player.
On Friday Intec Pharma (NASDAQ: NTEC) closed at $4.83 on only 601k shares. Today in the premarket the stock is up by 95% by barely reaching $10 on 2.5 million volume. That’s a very huge number before the market open. Perhaps, this week NTEC will cross $10 easily with the aid of biotech passioned investors who dream to beat oncology at all.
Biotech, Tech, and Crypto reporter
Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.